Vanguard Capital Management filed an amended beneficial ownership statement with the SEC on October 30, 2026, disclosing a 4.87% stake in Eledon Pharmaceuticals Inc, a pharmaceutical company headquartered in Irvine, California.

Key Highlights

  • Aggregate beneficial ownership: Vanguard Capital Management reported beneficial ownership of 3,957,862 shares of Eledon Pharmaceuticals common stock as of September 30, 2026.
  • Percent of class: The reported holdings represent 4.87% of the outstanding class of common stock (CUSIP 28617K101).
  • Sole voting power: Vanguard Capital Management reported sole voting power over 540,639 shares, with zero shares subject to shared voting power.
  • Sole dispositive power: The filing attributes sole dispositive power over all 3,957,862 shares to Vanguard Capital Management, with no shared dispositive power reported.
  • Amendment: This filing is Amendment No. 1 to a prior statement, triggered by a date-of-event of September 30, 2026.
  • Affiliates included: The filing covers securities held or managed through Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers LLC, and Vanguard Investments Australia Ltd.

Vanguard Capital Management Reports Ownership Position in Eledon Pharmaceuticals

According to the filing, Vanguard Capital Management, organized in Pennsylvania and operating as an investment adviser, reported aggregate beneficial ownership of 3,957,862 shares of Eledon Pharmaceuticals Inc common stock. Eledon Pharmaceuticals is a pharmaceutical issuer with principal executive offices at 19900 MacArthur Blvd, Suite 550, Irvine, CA 92612. The shares are listed on NASDAQ:ELDN. The ownership position reported in this amendment represents 4.87% of the class, placing it at or below the 5% threshold, as confirmed by Item 5 of the filing.

The filing explains that the reported position reflects securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and specified affiliates and business divisions, including Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers LLC, and Vanguard Investments Australia Ltd, in accordance with SEC Release No. 34-39538 (January 12, 1998). The filing further states that the position includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power, as well as securities held by clients over which the named affiliates or business divisions exercise dispositive and/or voting power.

Item 6 of the filing states that Vanguard Capital Management, including registered investment companies and other managed accounts, holds the right to receive, or the power to direct the receipt of, dividends and proceeds from the sale of the reported securities, and that "no one other person's interest in the securities reported herein is more than 5%." The filing was signed by My Trieu-Gatt, Authorized Signatory and Head of Global Fund Administration, on October 30, 2026.

What Was Disclosed

Vanguard Capital Management filed an amended beneficial ownership statement covering 3,957,862 shares of Eledon Pharmaceuticals common stock, equal to 4.87% of the class, with a triggering event date of September 30, 2026, and no shared voting or dispositive power reported.